Immunic, Inc.

Informe acción NasdaqCM:IMUX

Capitalización de mercado: US$158.0m

Immunic Dirección

Dirección controles de criterios 3/4

El CEO de Immunic es Daniel Vitt , nombrado en Apr 2019, tiene una permanencia de 7.08 años. compensación anual total es $2.31M, compuesta por 27.1% salario y 72.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.29% de las acciones de la empresa, por valor de $454.58K. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 5.5 años, respectivamente.

Información clave

Daniel Vitt

Chief Executive Officer (CEO)

US$2.3m

Compensación total

Porcentaje del salario del CEO27.05%
Permanencia del CEO7.1yrs
Participación del CEO0.3%
Permanencia media de la dirección4.8yrs
Promedio de permanencia en la Junta Directiva5.5yrs

Actualizaciones recientes de la dirección

Recent updates

Artículo de análisis • Oct 17

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jun 09

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Summary Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progression, a key regulatory endpoint, to confirm these promising results. We reiterate our Strong Buy rating, viewing the stock dip as a buying opportunity for investors with high-risk tolerance. Read the full article on Seeking Alpha
Seeking Alpha • Apr 28

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Summary Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and recent stock dilution, Immunic's market cap remains low, suggesting significant upside if clinical trials succeed. Vidofludimus calcium's unique dual action offers neuroprotection and anti-inflammatory benefits, positioning it as a potential next-gen oral MS treatment. Financial risks include ongoing cash burn and potential dilution, but management has a track record of successful fund-raising to support R&D efforts. Read the full article on Seeking Alpha
Artículo de análisis • Oct 25

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Jan 22

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Artículo de análisis • Jun 27

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 20

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic (NASDAQ:IMUX) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients. Shares of the micro-cap clinical-stage biopharma plunged 73.7% to $2.49 after hours. A pre-planned interim analysis of the early-stage trial found a greater decrease than expected in the so-called Psoriasis Area and Severity Index (PASI) in the placebo arm. The PASI is a widely used instrument in psoriasis trials that evaluates and grades the severity of psoriatic lesions and the patient's response to treatment. The trial enrolled a total of 41 patients who were randomized to get 150 mg once-daily and 150 mg twice-daily doses of IMU-935, along with placebo. "At this point, the company only has access to very limited information. The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period. Immunic does not yet have access to unblinded individual patient data," the company said in a statement. IMUX expects to continue IMU-935 development in psoriasis.
Seeking Alpha • Oct 10

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic (NASDAQ:IMUX) shares gained as much as 21% premarket on Monday after the clinical-stage biopharmaceutical company announced a $60M oversubscribed private placement equity financing. The company entered into a securities purchase agreement with select accredited investors and certain existing investors to issue and sell an ~8.69M shares of its common stock at $4.35/share and pre-funded warrants to purchase up to 5,096,552 common shares at $4.34/pre-funded warrant share. The pre-funded warrants will be immediately exercisable at $0.01 per share of common stock and remain exercisable until exercised in full. Gross proceeds from the equity financing is estimated to be around $60M. The financing is expected to close on Oct 12, 2022. Net proceeds will be used to fund Immunic's (IMUX) ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes. Proceeds, along with current cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into Q4/2024.
Seeking Alpha • Aug 04

Immunic GAAP EPS of -$0.72 in-line

Immunic press release (NASDAQ:IMUX): Q2 GAAP EPS of -$0.72 in-line. Cash and Cash Equivalents as of Q2  $88.1 million.
Artículo de análisis • Jul 27

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Apr 13

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • Dec 24

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Daniel Vitt en comparación con los beneficios de Immunic?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$104m

Dec 31 2025US$2mUS$625k

-US$97m

Sep 30 2025n/an/a

-US$103m

Jun 30 2025n/an/a

-US$102m

Mar 31 2025n/an/a

-US$96m

Dec 31 2024US$3mUS$610k

-US$101m

Sep 30 2024n/an/a

-US$97m

Jun 30 2024n/an/a

-US$95m

Mar 31 2024n/an/a

-US$98m

Dec 31 2023US$1mUS$585k

-US$94m

Sep 30 2023n/an/a

-US$129m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$125m

Dec 31 2022US$3mUS$520k

-US$120m

Sep 30 2022n/an/a

-US$85m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$79m

Dec 31 2021US$2mUS$399k

-US$93m

Sep 30 2021n/an/a

-US$83m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$1mUS$381k

-US$44m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$39m

Dec 31 2019US$2mUS$202k

-US$35m

Compensación vs. Mercado: La compensación total de Daniel($USD2.31M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.73M).

Compensación vs. Ingresos: La compensación de Daniel ha sido consistente con los resultados de la empresa en el último año.

CEO

Daniel Vitt (57 yo)

7.1yrs
Permanencia
US$2,311,272
Compensación

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic, Inc. since April 2019 and also served as its President until July 12, 2024. He is also managing director of Immunic Research GmbH in Ha...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Daniel Vitt
CEO & Director7.1yrsUS$2.31m0.29%
$ 454.6k
Jason Tardio
COO & President1.8yrsUS$1.21m0.0092%
$ 14.5k
Glenn Whaley
Chief Financial Officer6.1yrsUS$1.07m0.070%
$ 110.8k
Hella Kohlhof
Chief Scientific Officer9.3yrssin datossin datos
Jessica Breu
Head of Investor Relations & Communicationsno datasin datossin datos
Inderpal Singh
General Counsel4.9yrssin datossin datos
Patrick Walsh
Chief Business Officer4.6yrssin datossin datos
Werner Gladdines
Chief Development Officer1.8yrssin datossin datos
Michael A. Panzara
Chief Medical Officerless than a yearsin datossin datos
4.8yrs
Permanencia media
54yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de IMUX se considera experimentado (4.8 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Daniel Vitt
CEO & Director7.1yrsUS$2.31m0.29%
$ 454.6k
Barclay Phillips
Lead Independent Director6.5yrsUS$171.98k0.11%
$ 180.9k
Tamar Howson
Independent Director6.6yrsUS$149.82k0.11%
$ 180.9k
Jorg Neermann
Independent Director7.1yrsUS$156.98k0.15%
$ 232.0k
Paul Utz
Member of Scientific Medical Advisory Board5.5yrssin datossin datos
Duane Nash
Director7.3yrsUS$982.95k0.026%
$ 41.8k
Bruce Sands
Member of Scientific Medical Advisory Board5.5yrssin datossin datos
Fred Lublin
Member of Scientific Medical Advisory Board5.5yrssin datossin datos
Richard Rudick
Independent Director3.1yrsUS$149.48k0.17%
$ 267.2k
Jon Congleton
Independent Directorless than a yearsin datossin datos
Simona Skerjanec
Independent Interim Chairperson1.8yrsUS$149.14ksin datos
Thorvald Nagel
Independent Directorless than a yearsin datossin datos
5.5yrs
Permanencia media
60yo
Promedio de edad

Junta con experiencia: La junta directiva de IMUX se considera experimentada (5.5 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/20 05:44
Precio de las acciones al final del día2026/05/20 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Immunic, Inc. está cubierta por 17 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
George FarmerBMO Capital Markets Equity Research
William WoodB. Riley Securities, Inc.
Tyler BussianBrookline Capital Markets